Last updated on March 2019

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Brief description of study

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD.

The study has two parts:

  • Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks;
  • Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.

Clinical Study Identifier: NCT03720548

Contact Investigators or Research Sites near you

Start Over

Brain Matters Research

Delray Beach, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.